Back to Search

HOWARD SANDLER, MD

MD

Radiation Oncology Physician

NPI: 1508959800IndividualAccepts Medicare

Specialties, Licenses & Credentials

Radiation Oncology PhysicianPrimary

Radiology — Radiation Oncology

Code: 2085R0001X

MD227525(OR)4301054080(MI)

CMS Specialties

PrimaryRADIATION ONCOLOGY

Education

UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE

Class of 1985

Research & Publications (20)

Control of mRNA decay by phosphorylation of tristetraprolin.
PMID 18481987·Biochem Soc Trans·2008
6-review
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
PMID 17644123·J Urol·2007
6-review
Adjuvant postoperative radiotherapy following radical prostatectomy: is now the time?
PMID 16462848·Nat Clin Pract Oncol·2006
8-other
Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy.
PMID 15535441·J Urol·2004
6-review
Combined modality treatment for prostate cancer: role of chemotherapy.
PMID 12908140·Semin Oncol·2003
6-review
Dose escalation for prostate cancer: which dose for which person?
PMID 11842740·Front Radiat Ther Oncol·2002
6-review
Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy.
PMID 11020557·Int J Radiat Oncol Biol Phys·2000
4-observational
Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
PMID 19409729·Int J Radiat Oncol Biol Phys·2010
4-observational
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
PMID 19577865·Int J Radiat Oncol Biol Phys·2010
3-trial
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
PMID 19394158·Int J Radiat Oncol Biol Phys·2010
6-review
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
PMID 18990504·Int J Radiat Oncol Biol Phys·2009
3-trial
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
PMID 19636019·J Clin Oncol·2009
3-trial
Evaluating the relationships between rectal normal tissue complication probability and the portion of seminal vesicles included in the clinical target volume in intensity-modulated radiotherapy for prostate cancer.
PMID 19147014·Int J Radiat Oncol Biol Phys·2009
8-other
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
PMID 19470936·J Clin Oncol·2009
2-rct
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
PMID 19100600·Urology·2009
3-trial
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PMID 19103723·J Clin Oncol·2009
8-other
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
PMID 19047297·J Clin Oncol·2009
3-trial
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
PMID 19307511·J Clin Oncol·2009
2-rct
Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
PMID 18977098·Int J Radiat Oncol Biol Phys·2009
3-trial
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
PMID 19211454·J Natl Cancer Inst·2009
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3181 SW SAM JACKSON PARK RD, MAIL CODE CR 145
PORTLAND, OR 97239

Location

Practice Location

3181 SW SAM JACKSON PARK RD, PORTLAND, OR
(503) 494-6346

Quick Facts

NPI
1508959800
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
2
Locations
1
Years in Practice
41
Publications
20

Are you this provider?

Claim Your Profile